Table 3. Protective capacity of the SPI1-lon and SPI1-lon-fliC mutants after oral-oral-intravenous vaccination, followed by oral or intravenous challenge in chickens.

	4 DPV$			14 DPV			day 62of lifechallen.	4 DPI			14 DPI
vaccination	liver	spleen	caecum	Liver	spleen	caecum		liver	spleen	caecum	liver	spleen	caecum
SPI1-lon	4/6#	4.42±0.36	0/6	2/6	5/6	0/6	Oral	2/6	5/6	1/6*	0/6	2/6	0/6
SPI1-lon-fliC	4/6	4.21±0.48	0/6	1/6	6/6	0/6		0/6*	3/6	2/6	0/5	1/5	0/5
non-vaccinated	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.		6/6	6/6	6/6	2/6	3/6	0/6
SPI1-lon							i.v	1.94±0.94&	4.27±0.38&	4/6	4/6	2.25±1.26&	0/6
SPI1-lon-fliC								2.26±0.89&	4.49±0.41&	0/6*	1/6*	2.17±1.19&	0/6
non-vaccinated								4.73±0.70	6.50±0.56	5/6	6/6	4.06±0.67	1/6

^$DPV, days post intravenous vaccination.

^#number of positive chickens/number of tested.

^*χ² test different from the non-vaccinated control chickens at P<0.05.

^&t-test different from the non-vaccinated control chickens at P<0.05.